Ultrasound-guided fine-needle aspiration biopsy of thyroid nodules in patients taking novel oral anticoagulants.

ABSTRACT

BACKGROUND: Ultrasound-guided fine-needle aspiration biopsy (USGFNAB) is the most accurate form of evaluation for thyroid nodules. Many patients with thyroid nodules who present for USGFNAB are on anticoagulant agents, including the novel oral anticoagulants (NOACs), for stroke prevention in atrial fibrillation or venous thrombosis prophylaxis. SUMMARY: There has been at least one retrospective study describing neck USGFNAB bleeding risks in patients on antithrombotic and/or anticoagulant agents. This study concluded that there was no major bleeding risk or increase in hematoma formation in patients on antithrombotic or anticoagulant agents while undergoing USGFNAB, and there was no need to discontinue these agents prior to the procedure. With the emergence of NOACs, further recommendations should be made for patients on these agents who will be undergoing USGFNAB for thyroid nodules. Currently, there are no published studies regarding patients on NOACs who undergo USGFNAB. CONCLUSIONS: It has previously been established that patients on historical anticoagulant agents do not need to discontinue therapy prior to minor procedures such as needle aspirations or dental procedures. Therefore, in patients currently taking dabigatran, rivaroxaban, or apixaban, it is concluded that it is reasonable and safe to continue the novel oral anticoagulant agents prior to USGFNAB of thyroid nodules without major risk of bleeding. This conclusion is based not only on the fact that minor procedures are considered safe in patients on NOACs, but also because patients on historical anticoagulant agents do not need to discontinue therapy prior to minor procedures.